

# INDEX

## A

- Abdomen and pelvis fluids .....17–23
- Accurate mass and time (AMT) tag  
 approach .....176, 184  
 database .....183, 184
- Acetonitrile (ACN) .....38, 58, 86, 87,  
 146, 152, 168, 177, 178, 190, 196, 209, 210, 213
- Acrylamide/piperazine di-acrylamide (PDA)  
 solution .....108, 133
- Affinity chromatography ..... 4, 59, 64, 77, 86
- Affinity ligand .....56
- AIWA solution (acetonitrile, isopropanol,  
 ammonia)..... 58, 76
- Alcohol..... 17, 72, 143, 210
- Alzheimer's disease (AD) amyloid plaques .....171, 172
- AmiGO .....248
- (3-Aminopropyl) triethoxysilane (APTES) ..... 88, 89, 96
- Ammonium persulfate (APS) solution ..... 109, 114, 133
- Amniotic fluid .....17–18, 23
- Analysis of variance (ANOVA) .....148, 226
- Anionic proteins .....67, 69
- ANOVA. *See* Analysis of variance (ANOVA)
- Antibodies elution buffer..... 130, 132, 137
- Antibody-based microarrays.....4
- Anticoagulants.....4–6
- Aptamers .....4
- Area under the ROC curve (AUC) .....202, 228
- Arterial blood .....4, 6

## B

- BALF. *See* Bronchoalveolar lavage fluid (BALF)
- BCA. *See* Bicinchoninic acid (BCA)
- Benjamini & Hochberg False Discovery Rate.....201
- Bias..... 176, 225, 226, 234, 259, 266
- Bicinchoninic acid (BCA) ..... 47, 132, 189, 194, 195, 202  
 assay ..... 47, 194, 195, 202
- Bile ..... 18–19, 23, 192–195
- BioCarta ..... 94, 98, 239
- Biological replicates ..... 32, 33, 226, 234
- Biomarkers (BM)  
 high .....230  
 low .....230  
 qualification .....255–271  
 response .....257

- BioMart.....247
- Biomolecules .....140, 143, 147, 192, 242, 243
- b ions, y ions .....219
- Blocking ..... 9, 45, 49, 85, 131, 134,  
 136, 203, 225–227, 233, 234
- Blocking solution.....45, 49, 131, 134, 136
- Blood  
 collection ..... 4–6, 22, 89, 192  
 plasma..... 3–6, 8, 9, 22, 79  
 serum .....5–6, 22, 55, 65, 209
- Blue silver solution ..... 110, 117
- Body fluid collection, storage.....22–23
- Body fluid proteome ..... 8, 11, 14
- Body fluids-SOPs.....8–21
- Bonferroni correction ..... 231, 233, 239
- Bradford reagent.....106, 112, 177, 179, 211
- Breast milk .....14–15, 23
- Bronchoalveolar lavage fluid (BALF)..... 15–16, 23

## C

- Capillary electrophoresis coupled to mass spectrometry  
 (CE-MS)..... 31, 33, 36, 37, 39, 187–203
- Capillary zone electrophoresis (CZE).....196
- CAPS transfer buffer.....45, 53
- Cationic polypeptides.....67
- CBB. *See* Coomassie Blue Brilliant (CBB)
- Cell lines..... 31, 32, 37, 38, 129, 130, 132, 224
- Cell lysis .....30, 31, 38
- Cellular fractions .....29–40
- Cerebrospinal fluid (CSF) .....8–9, 22, 84, 189, 192–194
- Cerumen.....3
- Cervico-vaginal fluid (CVF) ..... 19–20, 23
- Chaotropic agents  
 guanidine .....72  
 urea .....72
- CHAPS. *See* 3-[3-(cholamidopropyl)-dimethylammonium]-  
 1-propanesulfonate (CHAPS)
- Chloroform..... 80, 145
- CHMP ..... 256, 257, 265, 267–270
- 3-[3-(Cholamidopropyl)-dimethylammonium]-1-  
 propanesulfonate (CHAPS) ..... 14, 35, 58,  
 76, 107, 121, 130
- Citrate .....4, 5, 79, 87, 88, 96
- Classifier..... 149, 198, 201

Cleaning sample solution ..... 130, 132  
 Clinical proteomics..... 3–23, 43–53,  
 151, 188, 197, 198, 203, 223, 225  
 ClueGO ..... 94–98, 242, 245, 247  
 Coercivity ..... 85  
 Collision induced dissociation (CID)..... 39, 219  
 Colostrum ..... 15  
 Combinatorial hexapeptide ligands ..... 59, 60  
 Combinatorial peptide ligand library (CPLL) ..... 56, 59,  
 63, 65–71, 73–78, 80, 118  
 beads..... 65–71, 73–80, 118  
 Companion diagnostics ..... 258, 265  
 Comparator ..... 258, 260–262  
 Conditioned medium (CM)..... 30–36, 38  
 Confirmatory BM development..... 260  
 Conventional secretion (i.e. signal  
 peptide-dependent) ..... 29  
 Coomassie blue brilliant (CBB) ..... 45, 47, 48, 50, 52  
 Co-precipitation ..... 85, 88  
 Covalent interactions..... 84, 85  
 CPLL. *See* Combinatorial peptide ligand library (CPLL)  
 Cresyl violet..... 150  
 Cryostat microtome..... 167, 168, 171  
 CVF. *See* Cervico-vaginal fluid (CVF)  
 Cytoscape ..... 94, 97, 240, 242–244, 246, 247

**D**

DAPI..... 150  
 DAVID..... 247  
 Decon2LS ..... 178  
 Δ..... 211, 228–230, 232  
 Depletion methods ..... 4, 166  
 Desalting  
 centrifugation ..... 78  
 gel-filtration..... 78  
 Desorption electrospray ionization (DESI)..... 159  
 Detector..... 91, 139, 140, 159, 196, 197, 202  
 Developer solution..... 110, 116  
 Diafiltration..... 65, 68–70, 78  
 Diagnostic/prognostic BM..... 258, 261  
 Dialysis ..... 31, 65, 68–70, 78  
 Difference gel electrophoresis (DIGE)..... 105, 224, 226  
 Differential centrifugation..... 31, 43–45  
 Disease classification ..... 188, 245–246  
 Dithioerythritol (DTE)..... 35, 130, 132  
 Dithiothreitol (DTT)..... 47, 57, 74, 107, 167, 177, 189, 210  
 Dye ligands..... 4

**E**

EDTA. *See* Ethylenediaminetetraacetic acid (EDTA)  
 Electrospray ionization (ESI) ..... 39, 140, 159,  
 190, 196, 197, 202, 219  
 Electrostatic interactions ..... 60, 63, 66, 67, 70–73, 75, 77, 79  
 Embedding..... 142–145, 152, 153

Endogenous peptides..... 214–216  
 Endoplasmic reticulum (ER)..... 31–36, 39  
 Endosomal compartment ..... 43  
 Enzymatic digestion ..... 142–144, 177,  
 179–180, 208, 210, 212–213  
 ESI. *See* Electrospray ionization (ESI)  
 Ethanol (EtOH)..... 87, 106, 110, 145,  
 146, 152–156, 159, 167, 168, 172, 188, 193  
 Ethylenediaminetetraacetic acid (EDTA) ..... 4, 5, 19,  
 79, 86, 107, 108  
 European Kidney and Urine Proteomics  
 (EuroKUP) ..... 7, 191  
 Experimental design..... 224–227, 234  
 Exploratory phase of BM development..... 260  
 Extracellular matrix ..... 29, 33, 243

**F**

False discovery rate (FDR) ..... 33, 39, 201, 231–233  
 Family-wise error rate (FWER) ..... 140, 192, 231, 233  
 Fetal bovine serum (FBS)..... 30, 37  
 FF samples ..... 143  
 Fiducial points..... 154, 158  
 Fixation ..... 142, 156  
 Fixing solution..... 110, 115, 116  
 Formaldehyde..... 110, 143  
 Formalin ..... 143, 156, 166  
 Formalin-fixed paraffin embedded (FFPE) tissues ..... 143  
 Fourier transform ion cyclotron resonance (FT-ICR)..... 140  
 FS44 filter set ..... 167–169  
 FWER. *See* Family-wise error rate (FWER)

**G**

GCP. *See* Good clinical practice (GCP)  
 Gelatin..... 144  
 GeLC-MS/MS ..... 183  
 Gel filtration chromatography..... 31, 37  
 Gene ontology (GO)..... 33, 94, 97, 98, 242, 248, 249, 251  
 Glomerulonephritis ..... 127–137  
 Glycoprotein enrichment ..... 83–98  
 Glycoproteome ..... 84, 86  
 Glycosylation..... 83–85, 93–94, 97, 105  
 Golgi apparatus ..... 31, 32, 35, 36  
 Good clinical practice (GCP)..... 258, 259, 264  
 Good laboratory practice (GLP) ..... 258, 259, 267  
 Graphical multidimensional maps..... 139  
 Guideline on clinical evaluation of diagnostic agents..... 258

**H**

Head and neck fluids..... 9–14  
 Hematoxylin & eosin (H&E) staining..... 150, 166, 169, 171  
 Hematuria ..... 7  
 Heparin ..... 5, 79, 92  
 HESI ..... 265–267  
 Hexapeptide ligand library ..... 4, 73, 79

Heymann nephritis (HN).....127  
 High-abundance proteins.....55, 56  
 Higher energy collision-induced dissociation (HCD).....39  
 HPPP. *See* HUPO Plasma Proteome Project (HPPP)  
 Human plasma proteome database.....4  
 Human Proteome Organization (HUPO).....4, 150  
 HUPO Plasma Proteome Project (HPPP).....4, 6  
 Hydrogen bonding.....60, 71–73, 75–77  
 Hydrophilic interaction liquid chromatography  
   (HILIC).....84  
 Hydrophobic associations.....60, 71–77, 79

**I**

ICAT.....105  
 IEF. *See* Isoelectric focusing (IEF)  
 Immobilized pH gradients (IPGs).....104, 105,  
   111, 118, 119  
 Immunoaffinity columns.....4  
 Immunoisolation.....44  
 Incubation solution.....110, 116  
 Indium tin oxide (ITO).....144, 145, 152–154, 156, 158  
 Inorganic components, silica.....85–86  
 Interactome.....241–243, 251  
 Interstitial fluid.....30  
 Iodoacetamide (IAA).....58, 87, 107, 120,  
   130, 167, 177, 189, 210  
 Ionic strength.....60, 63, 64, 66–69, 73  
 Ionization suppression.....143  
 Ion source.....139, 160, 213, 219  
 IPG re-hydration solution.....107–108, 114, 119  
 IPG strip equilibration buffer.....108, 115, 119  
 IRMa.....178, 183, 185  
 Isoelectric focusing (IEF).....103–108, 111,  
   113–115, 118, 119, 130, 132–133, 177, 178, 180  
 Isoelectric point.....67, 68, 71, 103, 104, 113, 180  
 Isopentane.....143  
*i*-SRM.....215

**K**

Kappa score.....249  
 Kyoto Encyclopedia of Genes and Genomes  
   (KEGG).....94, 97, 98, 239, 247, 248

**L**

Label-free quantitative analysis program  
   Max Quant.....171  
   Progenesis.....171  
   Sieve.....171  
 Laser beam.....140, 147, 166  
 Laser capture microdissection (LCM).....128–130, 165–173  
 Laser pyrolysis.....85  
 LCM. *See* Laser capture microdissection (LCM)  
 LC-MS/MS.....31, 33, 36–38, 80, 171,  
   176, 181–183, 207, 213, 215, 219

Lectin affinity.....84  
 Lectins  
   conavalin A (ConA).....88  
   maackia amurensis lectin (MA).....88  
   wheat germ agglutinin (WGA).....88  
 L HEPES buffer.....19  
 Lipid bilayer.....66  
 Liquid nitrogen.....5, 14  
 Log hazard ratio.....229, 230  
 Low abundance proteins.....20, 56, 59, 60,  
   63, 67, 104, 118, 120, 209  
 Low-copy number proteins.....29  
 Lyophilization.....31  
 Lyotropic salt.....64, 70

**M**

Magnetic nanoparticles (MNPs).....85–91, 96, 97  
 Magnetic nano-probe platform (MNP).....83–98  
 MALDI-TOF-MSI.....140, 142, 143, 151, 159, 190  
 Mann–Whitney U test.....200  
 Mass analyzer.....139, 140, 159, 209  
 Mass spectrometry (MS).....31, 33, 36–39, 76–78,  
   80, 84, 86, 87, 91–93, 97, 104–106, 111, 115–118,  
   122, 135, 139–161, 165–166, 169, 171, 175–178,  
   181–184, 187–203, 207–219, 224, 227, 233, 246  
 Mass-to-charge ratios (*m/z*).....139  
 Matrix  
   CHCA.....87, 145, 152, 157, 158  
   dihydroxybenzoic acid (DHB).....86, 152, 157, 158  
   ferulic acid.....145  
   sinapinic acid (SA).....145, 152, 155  
 Matrix-assisted laser desorption/ionization (MALDI)  
   imaging.....139–161  
 Median.....200, 229, 230, 233  
 Methylene blue.....150  
 Micelle synthesis.....85  
 Michigan Molecular Interactions (MiMI).....242, 243,  
   247, 248  
 Micro-dissected glomeruli.....129  
 Microsoft SQL database.....200  
 Migration time.....39, 199, 200  
 Milk proteins.....14  
 Minimum noise fraction (MNF).....149  
 MosaCluster.....198, 201  
 MosaiquesVisu.....39, 197, 199  
 MS Excel.....227, 233  
 Multidimensional protein identification technology  
   (MudPIT).....74, 105  
 Multivesicular bodies.....43

**N**

Nano liquid chromatography coupled online to MS  
   (nLC-MS).....166–168, 170, 171  
 Nanoparticles (NPs).....85, 86, 88, 89, 96

- Nanovesicles ..... 44, 47, 50  
Nasal lavage fluid (NLF) ..... 9–11  
Nasal secretions (mucus) ..... 9–10, 22  
Negative staining solution ..... 109, 116, 120, 122  
Nephrotoxicity ..... 265, 270  
Network biology ..... 237, 241, 245–246  
Nipple aspirate fluid (NAF) ..... 16–17, 23  
Nitrocellulose membrane ..... 48, 53, 131, 134  
*N*-linked glycosylation ..... 84, 85  
*N,N,N,N*-tetramethyl-ethylenediamine  
(TEMED) ..... 109, 114, 122, 131, 133  
Nodes ..... 95, 96, 149, 151, 242–244, 248  
Non-classical secretion ..... 33  
Non-vesicular pathways (e.g. ATP-binding cassette  
transporters) ..... 30  
Normalization ..... 45, 104, 118, 148, 197, 199–200, 266  
Null hypothesis ( $H_0$ ) ..... 227, 231
- O**
- O*-linked glycosylation ..... 84, 85  
On-tissue digestion ..... 143, 147, 151, 160  
Optimal cutting temperature (OCT)  
compound ..... 144, 152, 153  
Organic acid compound (matrix) ..... 140  
Organic components ..... 85  
Oxides ..... 85  
 $Y_2O_3$  ..... 86
- P**
- PALMRobo4.5Pro software ..... 167, 169, 170, 172  
Parallel reaction monitoring (PRM) ..... 209  
PathGuide ..... 238  
Peptide and protein identification  
Mascot ..... 171  
MaxQuant ..... 171  
Peaks ..... 171  
Sequest ..... 171  
X!Tandem ..... 171  
PeptideAtlas ..... 213, 218, 240  
Peptide ligand libraries ..... 4, 55–81  
Percentile ..... 227, 230, 231, 233  
Phosphate-buffered saline (PBS) ..... 20, 30, 33,  
35, 37, 44–46, 49, 51, 57, 64, 65  
Podocytes ..... 128–130  
Polyethylene naphthalate (PEN) membrane ..... 167  
Polymers ..... 47, 85, 140, 144, 202  
Poly[*N*-(2-hydroxypropyl)methacrylamide] (pHPMA) ..... 144  
Ponceau S stain ..... 45, 132, 134, 137  
Post-fixing solution ..... 110, 116  
Precipitation ..... 15, 31, 38, 39, 44, 46, 47, 51, 67, 70, 75,  
77, 79, 80, 97, 106, 112, 116, 121, 132, 177, 179, 212  
Pre-fractionation ..... 29  
Primary membranous nephropathy (MN) ..... 127–129
- Principal component analysis (PCA) ..... 149, 150, 153  
Probability ..... 79, 147, 225, 227, 231, 263, 268  
Prospective studies ..... 143, 264, 268  
Protease inhibitor ..... 5, 6, 13, 19, 20, 44,  
45, 65, 86, 89, 97, 132, 177  
Protein A ..... 4  
Protein arrays ..... 105  
Protein degradation ..... 143  
Protein-protein interaction (PPI) ..... 84, 118,  
237–239, 242, 243, 246, 247, 251  
Proteome enrichment ..... 31  
Proteomics analysis ..... 3, 4, 7, 37, 38  
proteotypic peptides ..... 213, 214, 217, 219
- Q**
- Qualification advice/opinion ..... 256, 265, 267–271  
Quantitative response-threshold ..... 257
- R**
- Randomization ..... 223, 225, 226, 233, 268  
RapiGest ..... 58, 160, 167, 169, 171, 173  
REACTOME ..... 239, 242, 248  
Receiver operating characteristic (ROC)  
curve ..... 201, 202, 227, 228, 268  
Region of interest (ROI) ..... 149, 150  
Re-hydration focusing solution ..... 130  
Remanence (residual magnetism) ..... 85  
Renal epithelial cells ..... 43  
Renal tubule cells ..... 43  
Replication ..... 225, 226, 266  
Resolution ..... 39, 104, 105, 119–121, 140, 142, 146, 147,  
151, 154, 159, 160, 172, 176, 182, 196, 200, 202, 209  
Resolving power ..... 140  
Retrospective studies ..... 143, 264, 268, 269  
ROC curve. *See* Receiver operating characteristic (ROC)  
curve  
ROI. *See* Region of interest (ROI)  
Rostrocaudal gradient ..... 9
- S**
- Saliva ..... 11–13, 22, 84, 88–90, 94, 95, 97  
Sample focusing solution ..... 130, 132  
Sample size ..... 159, 188, 224, 225, 227–230, 232–235, 270  
Saturation ..... 19, 56, 58, 59, 77, 79  
Savitzky-Golay filter ..... 148  
SBB. *See* Sudan Black B (SBB)  
SDS. *See* Sodium dodecyl sulfate (SDS)  
SDS-PAGE. *See* Sodium dodecyl sulfate-polyacrylamide gel  
electrophoresis (SDS-PAGE)  
SDS-PAGE running buffer ..... 46, 52, 109, 115, 131  
Secondary ion mass spectrometry (SIMS) ..... 159  
Secreted proteins ..... 29–40  
Secretome ..... 29–34, 38

Secretopeptidome .....29  
 Secretory pathway organelles..... 31–33, 35, 36  
 Sectioning..... 142–145, 153, 156  
 Selected reaction monitoring (SRM) ..... 207–209,  
 213–217, 219, 224  
 Seminal plasma.....20–23  
 Sensitivity ..... 104, 115, 116, 137, 142, 145,  
 146, 165, 188, 201–203, 207, 208, 232, 245, 263, 268  
 Serum free medium (SFM) ..... 30, 31, 35–38  
 Serum proteins ..... 30, 64, 74, 192  
 SID. *See* Stable isotope dilution (SID)  
 $\sigma^2$  ..... 228, 229, 263  
 Silica clot activator .....6  
 SIL synthetic peptides. *See* Stable isotope-labeled (SIL)  
 synthetic peptides  
 SIMS. *See* Secondary ion mass spectrometry (SIMS)  
 Sodium azide (NaN<sub>3</sub>) .....7  
 Sodium dodecyl sulfate (SDS).....19, 46, 57, 66,  
 67, 73–75, 80, 103, 108, 109, 114–116, 120, 122, 130,  
 131, 133, 188, 189  
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
 (SDS-PAGE) .....47, 48, 50, 52, 80, 97,  
 104, 105, 108–109, 111, 113, 115, 116, 118, 131, 133  
 Spatial distribution .....140  
 Spatial resolution..... 140, 142, 146, 154  
 Spectral alignment.....148  
 Spectral noise.....147  
 Spinal cord.....8  
 SRM. *See* Selected reaction monitoring (SRM)  
 SRMAtlas..... 213, 219  
 SRM-software  
 Pinpoint.....213, 215  
 Skyline (open-source) ..... 213, 215  
 Stable isotope dilution (SID).....209  
 Stable isotope-labeled (SIL) synthetic peptides..... 210, 214,  
 215, 217  
 Staining solution ..... 110, 116, 137  
 Standard of truth..... 258, 260, 261, 263, 266, 268–270  
 Statistical experimental design ..... 225–227, 234  
 Statistical significance test.....226  
 Stopper solution ..... 110, 116  
 Subcellular proteomics.....37  
 Sudan Black B (SBB) ..... 167, 168, 172  
 Support vector machines (SVM).....198, 201  
 Systems biology..... 241–246, 249, 251

**T**

Tamm Horsfall protein (THP)/uromodulin..... 46–48,  
 52, 183  
 TBS. *See* Tris buffered saline (TBS)  
 TBS containing 0.05% v/v Tween-20 (TBST)..... 131, 135  
 Tears ..... 13–14, 23  
 Tetraethyl orthosilicate (TEOS) solution..... 87, 88

$\theta$ ..... 228  
 Thioflavin S..... 166–172  
 Thorax fluids .....14–17  
 TIC. *See* Total ion count (TIC)  
 Time-of-flight (TOF)..... 88, 140, 143, 151, 190, 209  
 Time-to-event data ..... 229, 235  
 Tissue autofluorescence .....168, 172  
 TOF-SIMS instruments ..... 140, 159  
 Toluidine blue.....150  
 Total cellular proteome.....29  
 Total ion count (TIC) ..... 146, 148  
 Transition ..... 91, 208, 214, 215  
 Transmission electron microscopy .....46, 50  
 Triple quadrupole (QQQ)..... 160, 207–209, 213–215  
 Tris buffered saline (TBS) ..... 130–132, 135, 152  
 Trypan blue exclusion dye .....30  
 Trypsinization solution A (ammonium bicarbonate,  
 Rapigest SF) ..... 58, 78  
 Trypsinization solution B (sequencing  
 grade trypsin)..... 58, 78  
 Trypsin solution..... 152, 156, 171, 177, 210  
 $t$ -SRM ..... 213, 215  
 $t$ -test ..... 148, 200, 228  
 Two-dimensional gel electrophoresis  
 (2DE) ..... 37, 103–123, 127–137  
 Two-sample t-test..... 227–229, 235  
 Type I error..... 227, 231, 263  
 Type II error ..... 227, 263, 268

**U**

UCA solution. *See* Urea-citric acid (UCA) solution  
 Ultracentrifugation ..... 23, 44–47, 51  
 Ultrafiltration ..... 44, 46, 52, 341  
 UniProt.....218, 247  
 Urea ..... 6, 19, 35, 39, 58, 72, 73, 76,  
 79, 107, 108, 121, 130, 177, 189, 210, 212  
 Urea buffer.....14, 39, 58, 189, 193, 194  
 Urea-citric acid (UCA) solution .....58, 76  
 Urea-thiourea-CHAPS (UTC) solution.....58, 76  
 Urinary exosome positive markers  
 Alix .....49  
 CD9..... 49, 50  
 flotillin-1 ..... 49, 50  
 TSG-101 ..... 49, 50  
 Urinary exosomes .....43–53  
 Urine ..... 6–8, 17, 22, 29, 43–52, 84, 88–90,  
 94, 111, 117, 121, 175–185, 189, 191, 193–195,  
 198–200, 207–219, 266, 270

**V**

Van der Waal's interactions.....60, 71  
 Venipuncture ..... 4, 6, 192  
 Venous blood .....4, 6

Vesicular pathways (e.g. autophagy-based secretion) .....29–30  
VIPER..... 178, 183–185

**W**

Western blot transfer buffer.....131  
Within subject comparison.....261

**X**

Xylene..... 145, 155, 156

**Z**

z-test .....148